Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results

Olivier Lauche; Guila Delouya; Daniel Taussky; Cynthia Menard; Dominic Béliveau-Nadeau; Yannick Hervieux; Renée Larouche; Maroie Barkati

doi:10.5114/jcb.2016.59216

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

2/2016
vol. 8

Send email

Copy url:

abstract:

Original paper

Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results

Olivier Lauche

,

Guila Delouya

,

Daniel Taussky

,

Cynthia Menard

,

Dominic Béliveau-Nadeau

,

Yannick Hervieux

,

Renée Larouche

,

Maroie Barkati

J Contemp Brachytherapy 2016; 8, 2: 104–109

DOI: https://doi.org/10.5114/jcb.2016.59216

Online publish date: 2016/04/14

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Lauche O, Delouya G, Taussky D, et al. Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. Journal of Contemporary Brachytherapy. 2016;8(2):104-109. doi:10.5114/jcb.2016.59216.

APA

Lauche, O., Delouya, G., Taussky, D., Menard, C., Béliveau-Nadeau, D.,  & Hervieux, Y. et al. (2016). Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. Journal of Contemporary Brachytherapy, 8(2), 104-109. https://doi.org/10.5114/jcb.2016.59216

Chicago

Lauche, Olivier, Guila Delouya, Daniel Taussky, Cynthia Menard, Dominic Béliveau-Nadeau, Yannick Hervieux,  and Renée Larouche et al. 2016. "Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results". Journal of Contemporary Brachytherapy 8 (2): 104-109. doi:10.5114/jcb.2016.59216.

Harvard

Lauche, O., Delouya, G., Taussky, D., Menard, C., Béliveau-Nadeau, D., Hervieux, Y., Larouche, R.,  and Barkati, M. (2016). Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. Journal of Contemporary Brachytherapy, 8(2), pp.104-109. https://doi.org/10.5114/jcb.2016.59216

MLA

Lauche, Olivier et al. "Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results." Journal of Contemporary Brachytherapy, vol. 8, no. 2, 2016, pp. 104-109. doi:10.5114/jcb.2016.59216.

Vancouver

Lauche O, Delouya G, Taussky D, Menard C, Béliveau-Nadeau D, Hervieux Y et al. Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. Journal of Contemporary Brachytherapy. 2016;8(2):104-109. doi:10.5114/jcb.2016.59216.

Purpose: To validate the feasibility of a single-fraction high-dose-rate brachytherapy (HDRBT) boost for prostate cancer using real-time transrectal ultrasound (TRUS) based planning.

Material and methods: From August 2012 to September 2015, 126 patients underwent a single-fraction HDRBT boost of 15 Gy using real-time TRUS based planning. External beam radiation therapy (EBRT) (37.5 Gy/15 fractions, 44 Gy/22 fractions, or 45 Gy/25 fractions) was performed before (31%) or after (69%) HDRBT boost. Genito-urinary (GU) and gastro-intestinal (GI) toxicity were assessed 4 and 12 months after the end of combined treatment using the international prostate symptom score scale (IPSS) and the common terminology criteria for adverse events (CTCAE) v3.0.

Results: All dose-planning objectives were achieved in 90% of patients. Prostate D₉₀ ≥ 105% and ≤ 115% was achieved in 99% of patients, prostate V₁₅₀ ≤ 40% in 99%, prostate V₂₀₀ < 11% in 96%, urethra D₁₀ < 120% for 99%, urethra V₁₂₅ = 0% in 100%, and rectal V₇₅ < 1 cc in 93% of patients. Median IPSS score was 4 at baseline and did not change at 4 and 12 months after combined treatment. No patients developed ≥ grade 2 GI toxicity. With a median follow-up of 10 months, only two patients experienced biochemical failure. Among patients who didn’t receive ADT, cumulative percentage of patients with PSA ≤ 1 ng/ml at 4 and 18 months was respectively 23% and 66%.

Conclusions: Single-fraction HDRBT boost of 15 Gy using real-time TRUS based planning achieves consistently high dosimetry quality. In combination with EBRT, toxicity outcomes appear promising. A longer follow-up is needed to assess long-term outcome and toxicities.

keywords:

Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results

Olivier Lauche , Guila Delouya , Daniel Taussky , Cynthia Menard , Dominic Béliveau-Nadeau , Yannick Hervieux , Renée Larouche , Maroie Barkati

brachytherapy, HDR, prostate cancer, single fraction, TRUS

Olivier Lauche

,

Guila Delouya

,

Daniel Taussky

,

Cynthia Menard

,

Dominic Béliveau-Nadeau

,

Yannick Hervieux

,

Renée Larouche

,

Maroie Barkati